$1.20
+0.09 (+8.11%)
Open$1.14
Previous Close$1.11
Day High$1.20
Day Low$1.13
52W High$1.51
52W Low$0.51
Volume—
Avg Volume2.28M
Market Cap164.39M
P/E Ratio—
EPS$-0.69
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+1,957.5% upside
Current
$1.20
$1.20
Target
$24.69
$24.69
$14.59
$24.69 avg
$25.91
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.96M | 11.88M | 13.51M |
| Net Income | 575.0K | 486.8K | 473.9K |
| Profit Margin | 4.4% | 4.1% | 3.5% |
| EBITDA | 905.5K | 814.6K | 969.2K |
| Free Cash Flow | 454.1K | 555.8K | 696.0K |
| Rev Growth | -0.8% | +15.7% | +3.2% |
| Debt/Equity | 0.71 | 1.01 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |